If additional human studies provide evidence for a significant association between FGF21 expression and pathologic progression of PD, the results in study could help guide the design of clinical studies that evaluate the efficacy and safety of strategies such as FGF21 analogs treatment for improving motor and non‐motor deficits in patients with PD. This evidence concerns the gene FGF21 and Parkinson disease.